Are you interested in getting involved in research to further our understanding of celiac disease? See below for information about opportunities to become a participant in research studies.
Study of Celiac Disease Patients’ Strategies for Talking with Their Care Providers
The purpose of this study is to learn more about how celiac disease patients establish their credibility in conversations with their doctors and other care providers in order to secure diagnostic tests toward an accurate diagnosis. The body of literature within celiac disease research that this work hopes to add to is the scholarship on misdiagnosis.
This study consists of an online survey that will be administered to individual participants through PsychForum online – using Qualtrics (an online survey tool), etc. You will be asked to provide answers to a series of questions related to your experiences explaining symptoms to doctors and other care providers.
Participation in this study will require approximately 10 minutes of your time.
Giving of Consent
I have been given the opportunity to ask questions about this study. I have read this consent and I understand what is being requested of me as a participant in this study. I certify that I am at least 18 years of age. By clicking on the link below, and completing and submitting this anonymous survey, I am consenting to participate in this research.
Please contact Cathryn Molloy with any questions or for more information, at firstname.lastname@example.org or (540) 568-8018.
Refractory Celiac Disease
Celimmune, in partnership with the University of Chicago Celiac Disease Center, and Celiac Disease Foundation have joined forces to deploy the iCureCeliac® patient registry as a screen for phase 2 clinical study for refractory celiac disease type II. This is the first-ever use of the new and growing iCureCeliac® registry to support celiac disease therapeutic treatment development.
Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing immune-mediated diseases, has commenced screening patients in its Phase 2 clinical study for AMG 714, an investigational anti-IL-15 monoclonal antibody for the treatment of refractory celiac disease Type II (RCD-II). The randomized, double-blind, parallel-group study is expected to enroll 24 patients with a confirmed diagnosis of RCD-II. Study duration is 20 weeks and visits to the site take place every two weeks to receive intravenous infusion of AMG 714 or placebo. Intestinal biopsies will be taken before and after treatment to evaluate the efficacy of AMG 714. Patients enrolled will maintain a strict gluten-free diet during the study.
To see if you qualify to participate in the study, please contact email@example.com.